TM7SF2

Summary

TM7SF2 (transmembrane 7 superfamily member 2, HGNC:11863) is a protein-coding gene on chromosome 11q13.1, encoding Delta(14)-sterol reductase TM7SF2 (O76062). Catalyzes the reduction of the C14-unsaturated bond of lanosterol, as part of the metabolic pathway leading to cholesterol biosynthesis. It is a selective cancer dependency (DepMap: 11.2% of cell lines).

Enables Delta14-sterol reductase activity. Involved in cholesterol biosynthetic process. Located in endoplasmic reticulum. Part of receptor complex.

Source: NCBI Gene 7108 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 71 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 11.2% of screened cell lines
• MANE Select transcript: NM_003273

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11863
Approved symbol	TM7SF2
Name	transmembrane 7 superfamily member 2
Location	11q13.1
Locus type	gene with protein product
Status	Approved
Aliases	ANG1, DHCR14A, NET47
Ensembl gene	ENSG00000149809
Ensembl biotype	protein_coding
OMIM	603414
Entrez	7108

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 24 protein_coding, 9 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000279263, ENST00000345348, ENST00000524690, ENST00000524986, ENST00000525385, ENST00000526048, ENST00000526085, ENST00000526809, ENST00000527851, ENST00000527968, ENST00000528026, ENST00000528802, ENST00000529233, ENST00000529292, ENST00000529414, ENST00000529601, ENST00000530650, ENST00000530750, ENST00000530892, ENST00000531029, ENST00000531321, ENST00000532328, ENST00000533646, ENST00000533766, ENST00000534371, ENST00000534667, ENST00000881612, ENST00000881613, ENST00000881614, ENST00000881620, ENST00000881621, ENST00000881622, ENST00000881623, ENST00000934219, ENST00000970956, ENST00000970957, ENST00000970958, ENST00000970959

RefSeq mRNA: 2 — MANE Select: NM_003273 NM_001277233, NM_003273

CCDS: CCDS41669, CCDS60846

Canonical transcript exons

ENST00000279263 — 10 exons

Exon	Start	End
ENSE00002150317	65115893	65116230
ENSE00003488269	65111872	65112067
ENSE00003489545	65113220	65113414
ENSE00003497363	65112515	65112711
ENSE00003548026	65114713	65114832
ENSE00003618939	65112811	65112865
ENSE00003668365	65113491	65113594
ENSE00003784192	65115476	65115598
ENSE00003788378	65115314	65115394
ENSE00003789299	65114913	65115081

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 99.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.5382 / max 647.5938, expressed in 1604 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115026	21.5382	1604

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.24	gold quality
left adrenal gland cortex	UBERON:0035825	99.14	gold quality
adrenal cortex	UBERON:0001235	99.02	gold quality
right adrenal gland	UBERON:0001233	98.93	gold quality
left adrenal gland	UBERON:0001234	98.85	gold quality
adrenal tissue	UBERON:0018303	98.02	gold quality
adrenal gland	UBERON:0002369	98.01	gold quality
body of pancreas	UBERON:0001150	95.52	gold quality
endometrium epithelium	UBERON:0004811	95.51	gold quality
right lobe of liver	UBERON:0001114	95.44	gold quality
apex of heart	UBERON:0002098	95.41	gold quality
skin of abdomen	UBERON:0001416	94.87	gold quality
skin of leg	UBERON:0001511	94.49	gold quality
mammalian vulva	UBERON:0000997	94.27	gold quality
lower esophagus mucosa	UBERON:0035834	93.96	gold quality
prefrontal cortex	UBERON:0000451	93.74	gold quality
zone of skin	UBERON:0000014	93.25	gold quality
left ovary	UBERON:0002119	92.96	gold quality
liver	UBERON:0002107	92.33	gold quality
esophagus mucosa	UBERON:0002469	92.16	gold quality
right atrium auricular region	UBERON:0006631	92.12	gold quality
heart left ventricle	UBERON:0002084	91.91	gold quality
cardiac atrium	UBERON:0002081	91.86	gold quality
right frontal lobe	UBERON:0002810	91.81	gold quality
cardiac ventricle	UBERON:0002082	91.68	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.65	gold quality
cingulate cortex	UBERON:0003027	91.47	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.46	gold quality
anterior cingulate cortex	UBERON:0009835	91.45	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.36	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	28.85
E-ANND-3	yes	17.71
E-MTAB-9388	yes	10.74
E-MTAB-10596	no	244.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NFYA, SP1, SREBF2

miRNA regulators (miRDB)

12 targeting TM7SF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-5587-5P	99.07	68.58	838
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-5196-3P	97.57	65.98	979
HSA-MIR-4456	97.50	64.88	1678
HSA-MIR-4653-5P	97.22	67.72	1429

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• Results show that the TM7SF2 gene product SR-1 and six chimeras containing SR-1 and Neurospora erg-3 sequences fail to complement sterol c-14 reductase mutants in Neurospora and yeast. (PMID:11937680)
• a primary role in human cholesterol biosynthesis (PMID:16784888)
• LBR mutant variants and sterol reductases can severely interfere with the regular organization of the nuclear envelope and the endoplasmic reticulum. (PMID:19940018)
• Data suggest that, besides the SRE motif, both the inverted CCAAT-box and GC-box2 are essential for full TM7SF2 promoter activation by SREBP-2. (PMID:20138239)
• Twin enzymes, divergent control: The cholesterogenic enzymes DHCR14 and LBR are differentially regulated transcriptionally and post-translationally. (PMID:31911440)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tm7sf2	ENSDARG00000032816
mus_musculus	Tm7sf2	ENSMUSG00000024799
rattus_norvegicus	Tm7sf2	ENSRNOG00000020989

Paralogs (2): LBR (ENSG00000143815), DHCR7 (ENSG00000172893)

Protein

Protein identifiers

Delta(14)-sterol reductase TM7SF2 — O76062 (reviewed: O76062)

Alternative names: 3-beta-hydroxysterol Delta (14)-reductase, Another new gene 1 protein, C-14 sterol reductase, Putative sterol reductase SR-1, Sterol C14-reductase, Transmembrane 7 superfamily member 2

All UniProt accessions (14): O76062, E9PK81, E9PLI3, E9PLL1, E9PLS9, E9PP79, E9PQ50, E9PQZ7, E9PRQ1, E9PS09, E9PS18, H0YCI8, H0YDY5, H0YEN6

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the reduction of the C14-unsaturated bond of lanosterol, as part of the metabolic pathway leading to cholesterol biosynthesis.

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in adult heart, brain, pancreas, lung, liver, skeletal muscle, kidney, ovary, prostate, testis and adrenal gland, but not detected in placenta, spleen, thymus, small intestine, colon (mucosal lining), or peripheral blood leukocytes.

Induction. By sterol starvation.

Pathway. Steroid biosynthesis; cholesterol biosynthesis.

Similarity. Belongs to the ERG4/ERG24 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O76062-1	1	yes
O76062-2	2

RefSeq proteins (2): NP_001264162, NP_003264* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001171	ERG24_DHCR-like	Family
IPR018083	Sterol_reductase_CS	Conserved_site

Pfam: PF01222

Enzyme classification (BRENDA):

• EC 1.3.1.70 — DELTA14-sterol reductase (BRENDA: 16 organisms, 57 substrates, 84 inhibitors, 12 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4,4-DIMETHYL-5ALPHA-CHOLESTA-7,14-DIEN-3BETA-OL	0.0294–0.0345	3
NADPH	0.023–0.6	2
4ALPHA-METHYL-5ALPHA-ERGOSTA-8,14,24(28)-TRIEN-3	0.1	1
5ALPHA-CHOLESTA-8,14-DIEN-3BETA-OL	0.45	1
ERGOSTA-8,14-DIEN-3BETA-OL	0.06	1

Catalyzed reactions (Rhea), 3 shown:

• 4,4-dimethyl-5alpha-cholesta-8,24-dien-3beta-ol + NADP(+) = 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol + NADPH + H(+) (RHEA:18561)
• 5alpha-cholest-8,14-dien-3beta-ol + NADPH + H(+) = 5alpha-cholest-8-en-3beta-ol + NADP(+) (RHEA:46456)
• 4,4-dimethyl-8,14-cholestadien-3beta-ol + NADPH + H(+) = 4,4-dimethyl-5alpha-cholest-8-en-3beta-ol + NADP(+) (RHEA:46812)

UniProt features (21 total): binding site 8, transmembrane region 7, sequence variant 2, sequence conflict 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O76062-F1	94.07	0.88

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 338; 343; 350–351; 390; 394–398; 405; 311; 315

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-2426168	Activation of gene expression by SREBF (SREBP)
R-HSA-6807047	Cholesterol biosynthesis via desmosterol (Bloch pathway)
R-HSA-6807062	Zymostenol biosynthesis via lathosterol (Kandutsch-Russell pathway)
R-HSA-191273	Cholesterol biosynthesis

MSigDB gene sets: 198 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, JI_RESPONSE_TO_FSH_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, PEREZ_TP63_TARGETS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, chr11q13, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP, SHEPARD_BMYB_MORPHOLINO_DN, MODULE_66, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, KOYAMA_SEMA3B_TARGETS_UP

GO Biological Process (7): cholesterol biosynthetic process (GO:0006695), obsolete cholesterol biosynthetic process via lathosterol (GO:0033490), lipid metabolic process (GO:0006629), steroid biosynthetic process (GO:0006694), steroid metabolic process (GO:0008202), cholesterol metabolic process (GO:0008203), sterol biosynthetic process (GO:0016126)

GO Molecular Function (5): Delta14-sterol reductase activity (GO:0050613), NADP binding (GO:0050661), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor (GO:0016628)

GO Cellular Component (7): nuclear inner membrane (GO:0005637), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), signaling receptor complex (GO:0043235), membrane (GO:0016020), organelle membrane (GO:0031090)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cholesterol biosynthesis	2
Regulation of cholesterol biosynthesis by SREBP (SREBF)	1
Metabolism of steroids	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
sterol metabolic process	2
membrane	2
cholesterol metabolic process	1
sterol biosynthetic process	1
secondary alcohol biosynthetic process	1
primary metabolic process	1
steroid metabolic process	1
lipid biosynthetic process	1
lipid metabolic process	1
secondary alcohol metabolic process	1
steroid biosynthetic process	1
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	1
adenyl nucleotide binding	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on the CH-CH group of donors	1
organelle inner membrane	1
nuclear membrane	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cell periphery	1
protein-containing complex	1
cellular anatomical structure	1
membrane-bounded organelle	1

Protein interactions and networks

STRING

1318 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TM7SF2	ZNHIT2	Q9UHR6	902
TM7SF2	EBP	Q15125	896
TM7SF2	SQLE	Q14534	830
TM7SF2	SC5D	O75845	784
TM7SF2	CYP51A1	Q16850	782
TM7SF2	DHCR24	Q15392	739
TM7SF2	NSDHL	Q15738	736
TM7SF2	FDFT1	P37268	727
TM7SF2	MSMO1	Q15800	719
TM7SF2	HSD17B7	P56937	717
TM7SF2	LSS	P48449	702
TM7SF2	MVK	Q03426	697
TM7SF2	LMNB2	Q03252	671
TM7SF2	HMGCS1	Q01581	665
TM7SF2	MVD	P53602	664

IntAct

16 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CYSRT1	TM7SF2	psi-mi:“MI:0915”(physical association)	0.560
TM7SF2	LCE2C	psi-mi:“MI:0915”(physical association)	0.560
TM7SF2	CHRM4	psi-mi:“MI:0915”(physical association)	0.370
	AP3B1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
DISC1	AGRN	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC7A14	ESYT2	psi-mi:“MI:0914”(association)	0.350
MYB	A2ML1	psi-mi:“MI:0914”(association)	0.350
RAP2A	TM7SF2	psi-mi:“MI:0915”(physical association)	0.000
TM7SF2	CYSRT1	psi-mi:“MI:0915”(physical association)	0.000
TM7SF2	LCE2C	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-MS), LCE2C (Two-hybrid), CYSRT1 (Two-hybrid), TM7SF2 (Two-hybrid), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-RNA), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-MS), SWAP70 (Cross-Linking-MS (XL-MS)), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-MS), TM7SF2 (Affinity Capture-RNA)

ESM2 similar proteins: A0A8C2M425, A1L1J9, A1L504, A6NH21, A8WCG0, B0BNG2, F1RMN2, O43292, O75908, O76062, O77759, O88496, O88908, O89109, P38435, Q07175, Q0P4Y8, Q49LS0, Q5KR61, Q5RF50, Q5XK03, Q5ZKZ9, Q643R3, Q658P3, Q6MG14, Q6NVG1, Q767L9, Q7TN60, Q7TPN3, Q7TQM4, Q7ZWN0, Q8BKF1, Q8C3X8, Q8IUH8, Q8IZY2, Q8N130, Q8VC65, Q8WMV1, Q91YD1, Q9BU23

Diamond homologs: A0A1D8PIC7, G4SW86, I1RF79, I1RR90, I1RZZ3, O08984, O13597, O76062, O88455, P23913, P25340, P32462, P36209, P38670, P78575, Q01447, Q09195, Q14739, Q3U9G9, Q4WJ59, Q4WJJ9, Q4WKA5, Q4WW43, Q54PP1, Q5E9J5, Q5R7H4, Q5UQI4, Q6P4M0, Q71KT5, Q7SXF1, Q7ZXH1, Q8WMV1, Q9LDR4, Q9LDU6, Q9UBM7, Q9Z2Z8, A0A1D8PJ25, Q8MLV1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

71 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1450 predictions. Top by Δscore:

Variant	Effect	Δscore
11:65112893:GAGT:G	donor_gain	1.0000
11:65112896:T:G	donor_gain	1.0000
11:65113485:CTCCA:C	acceptor_loss	1.0000
11:65113488:CAGGC:C	acceptor_loss	1.0000
11:65113489:A:AG	acceptor_gain	1.0000
11:65113489:AGGC:A	acceptor_loss	1.0000
11:65113490:G:GG	acceptor_gain	1.0000
11:65113490:GGC:G	acceptor_gain	1.0000
11:65113590:GCTGG:G	donor_gain	1.0000
11:65113593:GG:G	donor_gain	1.0000
11:65113594:GG:G	donor_gain	1.0000
11:65113594:GGTA:G	donor_loss	1.0000
11:65113595:G:GG	donor_gain	1.0000
11:65113595:GT:G	donor_loss	1.0000
11:65113596:T:G	donor_loss	1.0000
11:65114708:CCCA:C	acceptor_loss	1.0000
11:65114709:CCA:C	acceptor_loss	1.0000
11:65114710:CAG:C	acceptor_loss	1.0000
11:65114711:A:AG	acceptor_gain	1.0000
11:65114711:AG:A	acceptor_gain	1.0000
11:65114712:G:GT	acceptor_gain	1.0000
11:65114712:GG:G	acceptor_gain	1.0000
11:65114712:GGT:G	acceptor_gain	1.0000
11:65114712:GGTC:G	acceptor_gain	1.0000
11:65114712:GGTCC:G	acceptor_gain	1.0000
11:65114829:CGAG:C	donor_loss	1.0000
11:65114830:GAG:G	donor_gain	1.0000
11:65114831:AGGTG:A	donor_loss	1.0000
11:65114832:GG:G	donor_loss	1.0000
11:65114834:T:A	donor_loss	1.0000

AlphaMissense

2648 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:65115544:C:G	H348D	0.997
11:65115354:A:C	K311N	0.995
11:65115354:A:T	K311N	0.995
11:65115331:T:C	F304L	0.994
11:65115333:C:A	F304L	0.994
11:65115333:C:G	F304L	0.994
11:65115353:A:T	K311I	0.993
11:65115563:A:C	D354A	0.993
11:65113348:A:C	S145R	0.992
11:65113350:C:A	S145R	0.992
11:65113350:C:G	S145R	0.992
11:65113558:A:C	K189N	0.992
11:65113558:A:T	K189N	0.992
11:65115531:G:C	W343C	0.992
11:65115531:G:T	W343C	0.992
11:65115563:A:T	D354V	0.992
11:65115003:A:C	S272R	0.991
11:65115005:C:A	S272R	0.991
11:65115005:C:G	S272R	0.991
11:65115365:G:C	R315P	0.991
11:65115529:T:A	W343R	0.991
11:65115529:T:C	W343R	0.991
11:65115552:C:A	N350K	0.991
11:65115552:C:G	N350K	0.991
11:65115583:T:A	W361R	0.991
11:65115583:T:C	W361R	0.991
11:65115563:A:G	D354G	0.990
11:65113592:T:A	W201R	0.989
11:65113592:T:C	W201R	0.989
11:65114831:A:T	E241V	0.989

dbSNP variants (sampled 300 via entrez): RS1000178121 (11:65110168 C>T), RS1000855590 (11:65112928 C>T), RS1000879214 (11:65112813 G>A), RS1002288541 (11:65112183 C>A,T), RS1002337128 (11:65111945 G>C,T), RS1002937925 (11:65114656 T>C), RS1003075415 (11:65114376 G>A,T), RS1003343870 (11:65113014 A>C,G), RS1003713003 (11:65114299 G>GC), RS1003909028 (11:65113625 G>A), RS1004350643 (11:65112447 G>A,T), RS1004813594 (11:65110729 A>G), RS1004875494 (11:65116433 G>A), RS1004884411 (11:65112234 G>A), RS1005083131 (11:65111122 C>G,T)

Disease associations

OMIM: gene MIM:603414 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5839 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	increases expression	5
bisphenol A	decreases expression, increases expression, affects expression	4
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	4
perfluorooctane sulfonic acid	decreases expression	3
Cyclosporine	decreases expression	3
bisphenol S	decreases expression, increases expression	2
Air Pollutants	increases oxidation, decreases expression, affects cotreatment, increases abundance	2
Nickel	decreases expression	2
Aflatoxin B1	affects expression, decreases expression	2
Particulate Matter	decreases expression, increases abundance	2
GSK-J4	decreases expression	1
afuresertib	increases expression	1
bisphenol F	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
propionaldehyde	increases expression	1
sodium arsenate	increases abundance, decreases expression	1
trichostatin A	decreases expression	1
beta-lapachone	decreases expression	1
afimoxifene	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	increases expression	1
cupric chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
yessotoxin	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
epoxiconazole	increases expression	1
monomethylarsonous acid	decreases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3539026	Binding	Inhibition of DHCR14 activity in human hepatocytes assessed as increase in FF-MAS level per gram of protein by GC-MS analysis (Rvb = 0.7 ug)	Inhibition of human sterol Δ7-reductase and other postlanosterol enzymes by LK-980, a novel inhibitor of cholesterol synthesis. — Drug Metab Dispos

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.